Daniel Jacoby, MD
Associate Professor AdjunctDownloadHi-Res Photo
Cards
Appointments
Cardiovascular Medicine
Primary
Contact Info
About
Titles
Associate Professor Adjunct
Biography
Dr. Daniel Jacoby specializes in the diagnosis and treatment of heart failure and cardiomyopathy.
Dr. Jacoby is the Founder and Director of the premier Cardiomypathy Program in the region, dedicated to serving the needs of patients, and families, living with the diagnosis of cardiomyopathy. Expert diagnosis and treatment of hypertrophic, dilated, arrhythmogenic and restrictive cardiomyopathies, as well as evaluation for causes of sudden cardiac death, are available through the Cardiomyopathy Program.
Dr. Jacoby has contributed widely to the literature of both heart failure and cardiomyopathy.
He serves as the Clinical Director of Innovation for Yale New Haven Health System. In this role Dr. Jacoby provides clinically oriented leadership for mission aligned bio-tech for internal and external partnerships and investments.
Last Updated on July 15, 2024.
Appointments
Cardiovascular Medicine
Associate Professor AdjunctPrimary
Other Departments & Organizations
- Adult Congenital Heart Program
- Cardiovascular Medicine
- Heart Transplant and Left Ventricular Assist Device Program
- Internal Medicine
- Yale Ventures
Education & Training
- Fellow
- Columbia Presbyterian Hospital (2007)
- Chief Fellow
- Columbia Presbyterian Hospital (2007)
- Resident
- Mount Sinai Hospital (2004)
- Chief Resident
- The Mount Sinai Hospital (2004)
- MD
- Yale School of Medicine (2000)
- BA
- Yale College, Judaic Studies (1993)
Research
Overview
Medical Research Interests
Amyloidosis; Clinical Trial; Genetics; Heart Failure; Heart Transplantation; Sleep
ORCID
0000-0002-9182-275X
Research at a Glance
Yale Co-Authors
Frequent collaborators of Daniel Jacoby's published research.
Publications Timeline
A big-picture view of Daniel Jacoby's research output by year.
Research Interests
Research topics Daniel Jacoby is interested in exploring.
Sangchoon Jeon, PhD
Tariq Ahmad, MD, MPH
Christopher Maulion, MD
Edward J Miller, MD, PhD
Nancy Schmieder Redeker, RN, MSN, PhD, FAHA, FAAN
Harlan Krumholz, MD, SM
95Publications
5,169Citations
Heart Failure
Heart Transplantation
Sleep
Amyloidosis
Publications
2025
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy 48-Week Results From FOREST-HCM
Saberi S, Abraham T, Choudhury L, Barriales-Villa R, Elliott P, Nassif M, Oreziak A, Owens A, Tower-Rader A, Rader F, Garcia-Pavia P, Olivotto I, Coats C, Fifer M, Sherrid M, Solomon S, Watkins H, Heitner S, Jacoby D, Kupfer S, Malik F, Melloni C, Meng L, Wei J, Maron M, Masri A, Committee and Investigators F. Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy 48-Week Results From FOREST-HCM. JACC Heart Failure 2025, 13: 102496. PMID: 40540987, DOI: 10.1016/j.jchf.2025.03.040.Peer-Reviewed Original ResearchAltmetricConceptsLeft ventricular ejection fractionOutflow tract gradientVentricular ejection fractionEjection fractionKansas City Cardiomyopathy Questionnaire-Clinical Summary ScorePeak left ventricular outflow tract gradientLeft ventricular outflow tract gradientMaximum left ventricular wall thicknessSymptomatic obstructive hypertrophic cardiomyopathyLeft atrial volume indexWeeks of follow-upAtrial volume indexObstructive hypertrophic cardiomyopathyFunctional class improvementLeft ventricular wall thicknessBaseline to weekFavorable cardiac remodelingNYHA functional class improvementRelief of obstructionCardiac biomarker levelsVentricular wall thicknessLong-term safetyDrug discontinuationLateral E/eOpen-labelEfficacy of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild Symptoms: Results from the SEQUIOA-HCM Trial
Maron M, Gimeno J, Veselka J, Barriales-Villa R, Claggett B, Coats C, Hegde S, Januzzi J, Kulac I, Masri A, Nassif M, Spertus J, Jacoby D, Heitner S, Kupfer S, Malik F, Wohltman A, Olivotto I, Zhang Y, Yang H, Shao C, Yuan Z, Zeng Q, Li X, Ma C, Wang Y, Shu Y, Chen M, Tao L, Li X, Wang J, Yu Z, Cheng X, Hong K, Zemanek D, Bundgaard H, Thune J, Jensen M, Mogensen J, Sygehus A, Hagege A, Habib G, Charron P, Lhermusier T, Trochu J, Reant P, Logeart D, Mitrovic V, Bekfani T, Edelmann F, Seidler T, Meder B, Schulze P, Stoerk S, Rassaf T, Merkely B, Zfat-Zwas D, Arad M, Halabi M, Paz O, Piltz X, Olivotto I, Targetti M, Metra M, Canepa M, Musumeci B, Emdin M, Michels M, Amin A, Knackstedt C, Oreziak A, Wojakowski W, Dudek D, Toste A, Bastos J, Barriales-Villa R, Pavia P, Blanes J, Urbano R, Alvarez A, Diaz L, Vera T, Elliott P, Coats C, Cooper R, Mahmod M, Bradlow W, Pantazis A, Esteban M, Masri A, Nassif M, Marian A, Owens D, Wheeler M, McGrew F, Bach R, Wever-Pinzon O, Collado E, Lauderdale F, Turer A, Hannawi B, Geske J, Owens A, Symanski J, Healthcare A, Kramer C, Sarswat N, Ahmad F, Abraham T, Markowitz J, Lakdawala N, Choudhury L, Jani S, Brinkley M, Bilen O, Asher C, Emani S, Sharma A, Fermin D, Lyle M, Raymer D, Darlington A, Maron M, Nielsen C, Wang A, Nagueh S, Martinez M, Desai M, Tower-Rader A, Kelly J, Rader F, Sen S, Bering P, Maurer M, Mitter S, Sherrid M, Wong T, Hussain Z, Saberi S, Naidu S, Enciso J. Efficacy of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild Symptoms: Results from the SEQUIOA-HCM Trial. European Heart Journal 2025, ehaf364. DOI: 10.1093/eurheartj/ehaf364.Peer-Reviewed Original ResearchAltmetricConceptsObstructive hypertrophic cardiomyopathyNew York Heart AssociationNew York Heart Association classKCCQ-CSSSecondary endpointsHypertrophic cardiomyopathyKansas City Cardiomyopathy Questionnaire Clinical Summary ScoreTreatment-emergent serious adverse eventsN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideMild symptomsOutflow tract gradientBaseline to weekModerate to severe symptomsClinical summary scoreSerious adverse eventsSymptom groupsClinically relevant outcomesPeak oxygen uptakePrimary endpointSymptomatic patientsNT-proBNPStatistically significant improvementNatriuretic peptideAficamtenAcoramidis for Transthyretin Amyloid Cardiomyopathy: Open-Label Extension Study Long-Term Follow-Up
Masri A, Aras M, Grogan M, Jacoby D, Maurer M, Shah S, Witteles R, Wong P, Ji A, DU J, Siddhanti S, Katz L, Sinha U, Fox J, Judge D. Acoramidis for Transthyretin Amyloid Cardiomyopathy: Open-Label Extension Study Long-Term Follow-Up. Journal Of Cardiac Failure 2025 PMID: 40216220, DOI: 10.1016/j.cardfail.2025.03.017.Peer-Reviewed Original ResearchCitationsAltmetricConcomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Masri A, Maron M, Abraham T, Nassif M, Barriales-Villa R, Bilen O, Coats C, Elliott P, Garcia-Pavia P, Massera D, Olivotto I, Oreziak A, Owens A, Saberi S, Solomon S, Tower-Rader A, Heitner S, Jacoby D, Melloni C, Wei J, Sherrid M, Olivotto I, Michels M, Barriales-Villa R, Garcia-Pavia P, Abraham T, Choudhury L, Kramer C, Lakdawala N, Maron M, Masri A, Nagueh S, Owens A, Rader F, Saberi S, Sherrid M, Symanski J, Tower-Rader A, Turer A, Wang A, Wong T, Zhang Y, Yang H, Shao C, Yuan Z, Zeng Q, Li X, Ma C, Wang Y, Shu Y, Chen M, Tao L, Li X, Wang J, Yu Z, Cheng X, Hong K, Zemanek D, Bundgaard H, Thune J, Jensen M, Mogensen J, Hagège A, Habib G, Charron P, Lhermusier T, Trochu J, Reant P, Logeart D, Mitrovic V, Bekfani T, Edelman F, Seidler T, Meder B, Schulze P, Stoerk S, Rassaf T, Merkely B, Zfat-Zwas D, Arad M, Halabi M, Paz O, Piltz X, Targetti M, Metra M, Canepa M, Musumeci B, Emdin M, Michels M, Amin A, Knackstedt C, Oreziak A, Wojakowski W, Dudek D, Toste A, Bastos J, Barriales-Villa R, Pavia P, Gimeno Blanes J, Hidalgo Urbano R, Alvarez A, Rincón Diaz L, Ripoll Vera T, Elliott P, Coats C, Cooper R, Mahmod M, Bradlow W, Pantazis A, Tome Esteban M, Masri A, Nassif M, Marian A, Owens D, Wheeler M, McGrew F, Bach R, Wever-Pinzon O, Collado E, Turer A, Hannawi B, Geske J, Owens A, Symanski J, Kramer C, Sarswat N, Ahmad F, Abraham T, Markowitz J, Lakdawala N, Choudhury L, Jani S, Brinkley D, Bilen O, Asher C, Emani S, Sharma A, Fermin D, Lyle M, Raymer D, Darlington A, Maron M, Nielsen C, Wang A, Nagueh S, Martinez M, Desai M, Tower-Rader A, Kelly J, Rader F, Sen S, Bering P, Maurer M, Mitter S, Sherrid M, Wong T, Hussain Z, Saberi S, Naidu S, Enciso J, Zemanek D, Bundgaard H, Jensen M, Mogensen J, Thune J, Donal E, Habib G, Hagege A, Logeart D, Reant P, Trochu J, Brandenburg S, Edelman F, Meder B, Rassaf T, Schulze P, Stoerk S, Merkely B, Arad M, Halabi M, Piltz X, Zfat-Zwas D, Emdin M, Musumeci B, Knackstedt C, Michels M, Oreziak A, Wojakowski W, Bastos J, Toste A, Bradlow W, Coats C, Cooper R, Elliott P, Pantazis A, Raman B, Tome Esteban M, Abraham T, Afshar K, Alsidawi S, Bering P, Bilen O, Brinkley D, Choudhury L, Darlington A, Desai M, Drakos S, Hannawi B, Hussain Z, Kelly J, Kramer C, Lakdawala N, Martinez M, Masri A, Mitter S, Moss N, Nagueh S, Naidu S, Nassif M, Owens A, Rader F, Ravi S, Rowin E, Saberi S, Sen S, Sherrid M, Enciso J, Rader A, Turer A, Wang A, Weiner S, Wong T, Zenker M. Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy. JACC Heart Failure 2025, 102441. PMID: 40285763, DOI: 10.1016/j.jchf.2025.03.008.Peer-Reviewed Original ResearchAltmetricConceptsSymptomatic obstructive hypertrophic cardiomyopathyObstructive hypertrophic cardiomyopathyLeft ventricular outflow tractLVOT obstructionOpen-labelHypertrophic cardiomyopathyObstructive hypertrophic cardiomyopathy patientsPlacebo add-on therapyEfficacy of concomitant useEpisodes of atrial fibrillationVentricular outflow tractAdd-on therapyCardiac myosin inhibitorCohort of patientsNegative inotropic propertiesWorsening of symptomsDisopyramide doseBackground therapyPlacebo-controlledCombination therapyNT-proBNPOutflow tractAficamtenConcomitant useClinical efficacyEFFECT OF AFICAMTEN TREATMENT FOR UP TO 72 WEEKS ON CARDIAC STRUCTURE AND FUNCTION IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: THE SEQUOIAHCM AND FOREST-HCM CMR SUB-STUDIES
Masri A, Cardoso R, Nassif M, Merkely B, Oreziak A, Abraham T, Villa R, Choudhury L, Coats C, Elliott P, Owens A, Rader F, Saberi S, Solomon S, Tower-Rader A, Heitner S, Jacoby D, Kupfer S, Malik F, Melloni C, Wei J, Wohltman A, Kramer C, Kwong R, Maron M. EFFECT OF AFICAMTEN TREATMENT FOR UP TO 72 WEEKS ON CARDIAC STRUCTURE AND FUNCTION IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: THE SEQUOIAHCM AND FOREST-HCM CMR SUB-STUDIES. Journal Of The American College Of Cardiology 2025, 85: 1247. DOI: 10.1016/s0735-1097(25)01731-0.Peer-Reviewed Original ResearchUNDERSTANDING THE IMPACT OF PLACEBO ON PATIENT-REPORTED HEALTH STATUS: AN ANALYSIS FROM SEQUOIA-HCM
Sherrod C, Nassif M, Choudhury L, Claggett B, Coats C, Maron M, Masri A, Miao Z, Olivotto I, Owens A, Saberi S, Butzner M, Heitner S, Jacoby D, Kupfer S, Malik F, Melloni C, Wohltman A, Spertus J, Investigators O. UNDERSTANDING THE IMPACT OF PLACEBO ON PATIENT-REPORTED HEALTH STATUS: AN ANALYSIS FROM SEQUOIA-HCM. Journal Of The American College Of Cardiology 2025, 85: 1344. DOI: 10.1016/s0735-1097(25)01828-5.Peer-Reviewed Original ResearchSAFETY AND OUTCOMES OF CONCOMITANT AFICAMTEN AND DISOPYRAMIDE USE AND WITHDRAWAL IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: AN ANALYSIS OF REDWOOD-HCM COHORT 3, SEQUOIA-HCM, AND FOREST-HCM TRIALS
Masri A, Abraham T, Nassif M, Barriales-Villa R, Bilen O, Coats C, Elliott P, Massera D, Olivotto I, Oreziak A, Owens A, Saberi S, Solomon S, Tower-Rader A, Heitner S, Jacoby D, Kupfer S, Malik F, Melloni C, Wei J, Wohltman A, Maron M, Sherrid M, on behalf of R. SAFETY AND OUTCOMES OF CONCOMITANT AFICAMTEN AND DISOPYRAMIDE USE AND WITHDRAWAL IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: AN ANALYSIS OF REDWOOD-HCM COHORT 3, SEQUOIA-HCM, AND FOREST-HCM TRIALS. Journal Of The American College Of Cardiology 2025, 85: 1160. DOI: 10.1016/s0735-1097(25)01644-4.Peer-Reviewed Original ResearchAficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy MAPLE-HCM Rationale, Study Design, and Baseline Characteristics
Garcia-Pavia P, Bilen O, Burroughs M, Costabel J, de Barros Correia E, Dybro A, Elliott P, Lakdawala N, Mann A, Nair A, Nassif M, Poulsen S, Reant P, Schulze P, Wang A, Berhane I, Heitner S, Jacoby D, Kupfer S, Malik F, Meng L, Sohn R, Wohltman A, Fifer M, Investigators M. Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy MAPLE-HCM Rationale, Study Design, and Baseline Characteristics. JACC Heart Failure 2025, 13: 346-357. PMID: 39909646, DOI: 10.1016/j.jchf.2024.11.011.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsObstructive hypertrophic cardiomyopathyStandard-of-careCardiac myosin inhibitorStandard-of-care medicationsBaseline characteristicsSymptomatic obstructive hypertrophic cardiomyopathyNondihydropyridine calcium channel blockersBaseline characteristics of patientsStandard-of-care drugsSecond-line therapyFirst-line therapyCalcium channel blockersCharacteristics of patientsImprove exercise capacityMyosin inhibitorFirst-lineBeta-blockersHypertrophic cardiomyopathyExercise capacityAlleviate symptomsPatientsAficamtenMedicationTherapyStudy design
2024
Aficamten and Cardiopulmonary Exercise Test Performance
Lee M, Masri A, Nassif M, Barriales-Villa R, Abraham T, Claggett B, Coats C, Gimeno J, Kulac I, Landsteiner I, Ma C, Maron M, Olivotto I, Owens A, Solomon S, Veselka J, Jacoby D, Heitner S, Kupfer S, Malik F, Meng L, Wohltman A, Lewis G, Wang A, Sherrid M, Kelly J, Marian A, Owens A, Wever-Pinzon O, Owens D, Wheeler M, Nagueh S, Rader F, McGrew F, Wong T, O'Neill T, Bach R, Martinez M, Lakdawala N, Collado E, Turer A, Desai Y M, Hussain Z, Tower-Rader A, Hannawi B, Geske J, Saberi S, Phelan D, Kramer C, Sarswat N, Ahmad F, Choudhury L, Markowitz J, Sen S, Bering P, Maron M, Jani S, Brinkley D, Naidu S, Maurer M, Moss N, Bilen O, Silva Enciso J, Fraser R, Akinboboye O, Asher C, Emani S, Sharma A, Fermin D, Lyle M, Raymer D, Darlington A, Resnic F, Nielsen C, Metra M, Musumeci B, Emdin M, Targetti M, Canepa M, Michels M, Knackstedt C, Amin A, Barriales Villa R, Garcia Pavia P, Gimeno Blanes J, Hidalgo Urbano R, Rincon Diaz L, Ripoll Vera T, Garcia Alvarez A, Zemanek D, Jensen M, Mogensen J, Thune J, Bundgaard H, Charron P, Trochu J, Habib G, Lhermusier T, Reant P, Hagege A, Logeart D, Mitrovic V, Edelmann F, Seidler T, Meder B, Schulze P, Stoerk S, Bekfani T, Rassaf T, Merkely B, Arad M, Halabi M, Zwas D, Piltz X, Paz O, Habib M, Dudek D, Oreziak A, Wojakowski W, Toste Batista A, Mesquita Bastos J, Elliott P, Mahmod M, Coats C, Cooper R, Bradlow W, Pantazis A, Tome Esteban M, McGinnis S, Campain J, Cocca-Spofford D, Giverts I, Griskowitz C, Newlands C, Moreno F. Aficamten and Cardiopulmonary Exercise Test Performance. JAMA Cardiology 2024, 9: 990-1000. PMID: 39230885, PMCID: PMC11375526, DOI: 10.1001/jamacardio.2024.2781.Peer-Reviewed Original ResearchCitationsAltmetricConceptsObstructive hypertrophic cardiomyopathySymptomatic obstructive hypertrophic cardiomyopathyBaseline to weekHypertrophic cardiomyopathyRandomized clinical trialsExercise performanceVentilatory efficiencyClinical trialsPrimary outcomeExercise testPlacebo-corrected improvementCardiac myosin inhibitorPhase 3 trialClinical measuresImpaired exercise capacityCardiopulmonary exercise testingExercise performance measuresHeart rate reserveSubmaximal exercise performancePeak heart rateClinically meaningful thresholdsPlacebo groupDouble-blindPlacebo-controlledAficamtenStandard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM
Masri A, Choudhury L, Barriales-Villa R, Elliott P, Maron M, Nassif M, Oreziak A, Owens A, Saberi S, Tower-Rader A, Rader F, Garcia-Pavia P, Olivotto I, Nagueh S, Wang A, Heitner S, Jacoby D, Kupfer S, Malik F, Melloni C, Meng L, Wei J, Sherrid M, Abraham T, Investigators F. Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM. Journal Of The American College Of Cardiology 2024, 84: 1839-1849. PMID: 39477631, DOI: 10.1016/j.jacc.2024.09.002.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsObstructive hypertrophic cardiomyopathyKansas City Cardiomyopathy Questionnaire-Clinical Summary ScoreStandard-of-careSOC therapyAdverse eventsDose reductionTherapy withdrawalHypertrophic cardiomyopathyTreatment of obstructive hypertrophic cardiomyopathyPro-B-type natriuretic peptide levelsN-terminal pro-B-type natriuretic peptide levelsTreatment-emergent adverse eventsHigh-sensitivity troponin IOutflow tract gradientEmergent adverse eventsNYHA functional classFirst-line therapyNatriuretic peptide levelsOff-target side effectsSummary scoreControlled clinical trialsMeasures of efficacyClinical measures of efficacyStable doseNo withdrawals
Academic Achievements & Community Involvement
Activities
activity Section of Cardiovascular Disease Fellowship Training Program
2010 - PresentCommitteesMemberDetailsParticipate in candidate interview and selection processactivity Pediatric Cardiology Chief Search Committee
2011 - PresentCommitteesMemberDetailsReviewed candidate options. Interviewed candidates. Provided feedback and participated in debate and discussion in the selection of the Pediatric Cardiology Chief position.activity Quality Assurance and Process Improvement Committee Co-Chair
02/01/2014 - PresentCommitteesCo-ChairDetailsReview regulatory and quality metrics. Guide program through regulatory visits. Identify and improve on existing program structure for growth, quality, and efficiency. Solicit input from faculty and staff regarding program function. Establish metrics for dashboard population and review. Supervise development of internal metrics dashboard. Report out to Yale New Haven Transplant Center Quality Assessment and Process Improvement meeting.activity Advanced Heart Failure Recipient Review Committee Co-Chair
02/01/2014 - PresentCommitteesCo-ChairDetailsOrganize structure and process around recipient review for advanced heart failure therapies (left ventricular assist devices and heart transplant). Arbitrate and act as final decision maker with Co-Chair (Surgical Director of Advanced Heart Failure) regarding transplant listing and device implant decisions for patients brought up for consideration. Supervise nursing and coordinator staff in recipient evaluation. Review any and all issues that arise in the course of the week regarding transplant listed patients. Establish and maintain heart transplant and LVAD protocols and pathways.activity Clinical Operations Committee - Section of Cardiovascular Diseases
2018 - PresentCommitteesMemberDetailsRepresent the Comprehensive Heart Failure Program contributing to Cardiovascular Disease Section initiatives and clinical operations planning. Participate in Section vision and mission discussions particularly regarding clinical operations and contribute meaningful, actionable plans and perspectives to support and grow the Section of Cardiovascular Diseases on behalf of the faculty, staff, and patients we serve.
Honors
honor Teacher of the Year
05/01/2008Yale School of Medicine AwardYale New Haven Hospitalist ProgramDetailsUnited Stateshonor Humanism in Medicine
06/15/2004Other AwardAlpha Omega AlphaDetailsUnited States
News & Links
Related Links